Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen Aminopeptide Oral Solution for prevention and treatment of seasonal allergic rhinitis in children
ChiCTR2300073443Phase 4Completed
- Sponsor
- Beijing Children's Hospital
- Start
- Jul 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spleen polypeptide in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Symptom score at week 12 and Drug score at week 12. Started Jul 2022; status: completed.
02
Drugs
spleen polypeptide
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2300073443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073443.